Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24067502 | 0.83 | CYP19A1 (0.38) | CYP19A1LMNAKCNA5CYP1A2CYP3A4 | |
| SCHEMBL11700013 | 0.73 | KCNA5 (0.50) | CYP19A1LMNAKDM4EKCNA5CYP1A2 | |
| SCHEMBL25490043 | 0.71 | ALDH1A1 (0.42) | PTGER2ALDH1A1LMNAKDM4ENPSR1 | |
| SCHEMBL882396 | 0.71 | CYP19A1 (0.46) | CYP19A1LMNAKCNA5CYP1A2CYP3A4 | |
| SCHEMBL10191716 | 0.70 | CYP19A1 (0.52) | CYP19A1LMNAKCNA5CYP1A2CYP3A4 | |
| SCHEMBL26159537 | 0.70 | CYP11B2 (0.41) | CYP19A1ALDH1A1LMNAKDM4ECYP1A2 | |
| SCHEMBL22766246 | 0.69 | CYP19A1 (0.50) | CYP19A1LMNAKCNA5CYP1A2CYP3A4 | |
| SCHEMBL20781386 | 0.69 | CYP19A1 (0.50) | CYP19A1LMNAKCNA5CYP1A2CYP3A4 | |
| SCHEMBL2421346 | 0.69 | CYP19A1 (0.50) | CYP19A1LMNAKCNA5CYP1A2CYP3A4 | |
| SCHEMBL30634152 | 0.69 | TAAR1 (0.57) | CYP19A1LMNAKCNA5CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20210371441-A1 | PLATINUM COMPLEX, ITS PREPARATION AND THERAPEUTIC USE | CITY UNIVERSITY OF HONG KONG (HK) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371441-A1 | PLATINUM COMPLEX, ITS PREPARATION AND THERAPEUTIC USE | IDH1, IDH2, IDH3A | CYP19A1 3877/4885PTGER2 1914/4885ALDH1A1 1791/4885 |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINE1, SERPINA3 | CYP19A1 2792/4885PTGER2 2254/4885ALDH1A1 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.